We have previously reported the poor prognostic impact of WT1 mutations in a large series of pediatric patients with AML, both in the entire group of patients as well as in those with CN-AML. Moreover, we identified a group with poor prognostics, characterized by the combined presence of a WT1 mutation and an FLT3-ITD.
We also described the presence of SNP rs16754, which was distributed equally between WT1-mutated and WT1 wild-type samples, but we did not report its association with outcome. Furthermore, only a few samples were analyzed for WT1 mRNA expression in our series.
Primed by the paper from Damm et al, we have now performed a full analysis of the characteristics and prognostic impact of WT1 SNP rs16754 and WT1 mRNA expression in pediatric AML.